Loading…
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $65M | $-71M | $-82M | $-32M | -126.5% | -3.4% | -29.4% |
| 2024 | $68M | $-105M | $-116M | $-97M | -90.1% | -14.6% | -13.3% |
| 2023 | $79M | $-123M | $-134M | $-112M | -61.7% | -8.1% | 9.9% |
| 2022 | $86M | $-119M | $-122M | $-87M | -37.9% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 86.16 | 79.20 | 67.64 | 65.32 |
| Operating Revenue | - | 86.16 | 79.20 | 67.64 | 65.32 |
| Operating Expense | - | 210 | 216.41 | 189.33 | 150.67 |
| Research And Development | - | 164.52 | 163.52 | 131.48 | 106.74 |
| Selling General And Administration | - | 45.48 | 52.89 | 57.85 | 43.93 |
| Total Expenses | - | 210 | 216.41 | 189.33 | 150.67 |
| Operating Income | - | -123.84 | -137.21 | -121.69 | -85.35 |
| Total Operating Income As Reported | - | -123.84 | -137.21 | -121.69 | -85.35 |
| EBITDA | - | -119.22 | -123.48 | -104.51 | -71.28 |
| Normalized EBITDA | - | -119.30 | -123.48 | -104.58 | -71.32 |
| EBIT | - | -122.19 | -125.85 | -106.85 | -75.87 |
| Interest Income | - | 1.57 | 11.36 | 14.77 | 9.44 |
| Interest Expense | - | 0 | 5.15 | 10.94 | 7.68 |
| Net Interest Income | - | 1.57 | 6.21 | 3.83 | 1.76 |
| Other Non Operating Income Expenses | -0.03 | 0.08 | - | - | - |
| Other Income Expense | -0.03 | 0.08 | - | 0.07 | 0.04 |
| Interest Income Non Operating | - | 1.57 | 11.36 | 14.77 | 9.44 |
| Interest Expense Non Operating | - | 0 | 5.15 | 10.94 | 7.68 |
| Net Non Operating Interest Income Expense | - | 1.57 | 6.21 | 3.83 | 1.76 |
| Pretax Income | - | -122.19 | -131 | -117.79 | -83.55 |
| Tax Provision | - | -0.43 | 2.82 | -1.74 | -1.66 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -121.76 | -133.82 | -116.04 | -81.89 |
| Net Income From Continuing And Discontinued Operation | - | -121.76 | -133.82 | -116.04 | -81.89 |
| Net Income From Continuing Operation Net Minority Interest | - | -121.76 | -133.82 | -116.04 | -81.89 |
| Net Income | - | -121.76 | -133.82 | -116.04 | -81.89 |
| Net Income Common Stockholders | - | -121.76 | -133.82 | -116.04 | -81.89 |
| Net Income Including Noncontrolling Interests | - | -121.76 | -133.82 | -116.04 | -81.89 |
| Normalized Income | - | -121.84 | -133.82 | -116.12 | -81.93 |
| Diluted NI Availto Com Stockholders | - | -121.76 | -133.82 | -116.04 | -81.89 |
| Basic Average Shares | - | 20.60 | 20.97 | 21.16 | 21.34 |
| Diluted Average Shares | - | 20.60 | 20.97 | 21.16 | 21.34 |
| Reconciled Depreciation | - | 2.97 | 2.37 | 2.34 | 4.59 |
| Total Unusual Items | -0.03 | 0.08 | - | 0.07 | 0.04 |
| Total Unusual Items Excluding Goodwill | -0.03 | 0.08 | - | 0.07 | 0.04 |
| Gain On Sale Of Security | -0.03 | 0.08 | - | 0.07 | 0.04 |
| General And Administrative Expense | - | 45.48 | 52.89 | 57.85 | 43.93 |
| Other Gand A | - | 45.48 | 52.89 | 57.85 | 43.93 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc.this co. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Atea Pharmaceuticals, Inc. | AVIR | $354M | -2.23 | 1.28 | -57.5% | -1.43 |
| Greenwich LifeSciences, Inc. | GLSI | $347M | -21.99 | 136.99 | -623.1% | - |
| Larimar Therapeutics, Inc. | LRMR | $342M | - | 4.38 | -212.2% | - |
| Verastem, Inc. | VSTM |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $339M |
| -1.62 |
| 5.93 |
| -366.2% |
| -1.07 |
| Simulations Plus, Inc. | SLP | $336M | -5.20 | 2.70 | -51.9% | 20.82 |
| 908 Devices Inc. | MASS | $334M | 17.11 | 2.32 | 13.6% | -12.61 |
| Abeona Therapeutics Inc. | ABEO | $332M | 4.66 | 2.08 | 44.7% | 3.54 |
| Humacyte, Inc. | HUMA | $331M | -8.10 | 106.40 | -1313.4% | -15.52 |
| Peer Median | - | -2.23 | 3.54 | -134.8% | -1.25 | |